Chemed (CHE) shares have climbed to $493.23, marking a 26.2% increase over the past six months. This performance has allowed the stock to outperform the S&P 500 by 11.9%. Despite this recent momentum, analysts at StockStory express limited confidence in the company's long-term business quality, citing specific weaknesses in sales growth and profitability trends.
The primary concern centers on Chemed's revenue trajectory. Over the last five years, the company's sales grew at a compounded annual growth rate of 4.1%. Analysts describe this pace as mediocre, noting it falls below their standard for the healthcare sector. They argue that while any business can deliver a strong quarter, enduring quality is typically demonstrated through consistent growth over several years.
Profitability metrics further complicate the investment case. Chemed's adjusted operating margin, which reflects revenue remaining after core expenses like wages and advertising, decreased by 3.9 percentage points over the past five years. The trailing 12-month adjusted operating margin stands at 13.5%. Analysts point out that with higher revenue, the company should have benefited from economies of scale, leading to better profitability. The failure to see this improvement raises questions about the efficiency of Chemed's expense base.
Another key indicator, return on invested capital (ROIC), has also declined in recent years. ROIC measures how much operating profit a company generates relative to its total capital, including debt and equity. The downward trend in this metric suggests that Chemed may be facing fewer profitable growth opportunities, a symptom that analysts view with caution despite acknowledging past management performance.
With the stock trading at a fair valuation multiple, analysts consider the current price reasonable. However, they maintain that the underlying business quality does not meet their standards for a strong buy recommendation. Instead of adding Chemed to a portfolio, they suggest investors look toward other opportunities in emerging markets or high-growth sectors. The report specifically highlights potential in Latin American equities as an alternative to Chemed's current risk profile.
The broader market context involves rapid rotation between quality stocks and expensive valuations. Analysts note that artificial intelligence is disrupting sectors quickly, requiring investors to distinguish between fundamentally strong companies and those trading at premium prices. While Chemed has been a "great trade" recently due to its price action, the fundamental data points to slowing growth and shrinking margins that warrant caution for long-term holders.